Ciwon daji na Pancreatic: Sabbin Zaɓuɓɓukan Jiyya

A cikin yaƙi da ciwon daji na pancreatic, sababbin gwaje-gwaje na asibiti sun zama masu mahimmanci. Waɗannan gwaje-gwajen suna ba wa marasa lafiya da wuri damar yin amfani da jiyya na yanke-yanke wanda zai iya haifar da ci gaba a cikin bincike da fatan samun sakamako mafi kyau. 

Kowane magani da ake samu a yau an fara bincike ne, haɓakawa kuma an yarda da shi ta hanyar gwaji na asibiti - binciken bincike wanda ke bincika sabbin jiyya ko haɗaɗɗun jiyya don sanin ko suna da amfani ga mutanen da ke zaune tare da ciwon daji na pancreatic. Ciwon daji na pancreatic yana ƙara zama babban abin damuwa a duniya, koyaushe yana motsa buƙatar sabbin hanyoyin jiyya da ƙoƙarin haɓaka magunguna. Bukatun da ba a biya su ba da ke da alaƙa da cutar yana jan hankalin kamfanoni da yawa don saka hannun jari a masana'antar. Waɗannan abubuwan haɗin gwiwa tare da hauhawar kashe kuɗin kiwon lafiya a duk duniya za su haɓaka haɓakar kasuwa. Rahoton daga Insight Market Insight ya ce ana sa ran girman Kasuwar Maganin Ciwon Kankara zai samar da ɗimbin kudaden shiga tsakanin shekarar 2021 zuwa 2027. Rahoton ya ci gaba da cewa: “Canwon daji na pancreatic ana ɗaukarsa ɗaya daga cikin nau'ikan ciwon daji mafi muni wanda ya samo asali daga kyallen pancreatic kuma yana iya sauri. yada zuwa gabobin da ke kusa. Zaɓin salon rayuwa mara kyau kamar shan taba, barasa da shan taba gami da cututtukan da ke da alaƙa da salon rayuwa kamar kiba da ciwon sukari na cikin manyan abubuwan da ke haifar da ciwon daji na pancreatic. Ƙungiyar Cancer ta Amurka ta kiyasta cewa fiye da Amirkawa 60,000 za su kamu da ciwon daji na pancreatic a cikin 2021. Ana ganin irin wannan yanayin a wasu sassan duniya da dama wanda zai inganta yanayin masana'antu." Ayyukan fasahar kere-kere da kamfanonin harhada magunguna a kasuwanni a wannan makon sun hada da Oncolytics Biotech® Inc., Bristol Myers Squibb, Seagen Inc., Exact Sciences Corp., Kura Oncology, Inc.

Insight Market Insight ya kara da cewa: “Chemotherapy, immunotherapy, far da aka yi niyya, da kuma maganin hormone, da sauransu, su ne nau’ikan hanyoyin magance cutar kansa na pancreatic. Daga cikin waɗannan, ɓangaren jiyya da aka yi niyya yana yiwuwa ya mallaki kaso mai kyau na kasuwa nan da 2027. Maganin da aka yi niyya ya yi niyya ga takamaiman sunadaran ƙwayoyin cuta, ƙwayoyin cuta, ko kyallen jikin da ke ba da gudummawa ga haɓakar cutar kansa. Maganin yana toshe girma da yaduwar ƙwayoyin cutar kansa yayin da yake iyakance lalacewa ga masu lafiya. Maganin da aka yi niyya zai lura da karuwar buƙatun maganin ciwon daji na pancreatic a cikin shekaru masu zuwa. "

Oncocolytics Biotech® yana ba da cikakken sabuntawa game da shari'ar cutar ta pancokin-lokaci - PROCYTICS Biotech®) a yau sanar da nasarar karewar lafiya mai haƙuri da cutar ciwon kare mataki na 1/2 GOBLET binciken biyo bayan kimantawa ta Hukumar Kula da Kare Bayanai (DSMB). DSMB ba ta lura da damuwa na aminci a cikin waɗannan marasa lafiya ba kuma ta ba da shawarar ci gaba da binciken kamar yadda aka tsara. Ana ci gaba da ci gaba da gudana cikin aminci don ƙungiyar ƙwararrun cutar sankara mai launin fata ta layi na uku.

Ana gudanar da binciken GOBLET ta hanyar AIO, babban ƙungiyar ilimin likitancin likitancin ilimin likitanci da ke Jamus, kuma an tsara shi don kimanta aminci da ingancin pelareorep a hade tare da Roche's anti-PD-L1 inhibitor atezolizumab a cikin marasa lafiya tare da pancreatic metastatic, metastatic. colorectal, da ci-gaban ciwon daji na dubura. Binciken ya ci gaba da gudana kuma ana sa ran yin rajistar marasa lafiya a wuraren gwaji na asibiti 14 a duk faɗin Jamus.

Ƙungiyar ciwon daji na pancreatic na binciken GOBLET ya ƙaddamar da bayanan asibiti da aka ruwaito a baya wanda ke nuna haɗin gwiwa da aikin rigakafin ciwon daji na pelareorep hade tare da hana bincike a cikin masu ciwon daji na pancreatic wadanda suka ci gaba bayan jiyya na farko (haɗi zuwa PR, haɗi zuwa poster). Har ila yau, yana ginawa a kan bayanan asibiti na farko wanda ya nuna fiye da 80% karuwa a cikin tsaka-tsaki na ci gaba ba tare da rayuwa ba a cikin marasa lafiya na ciwon daji tare da ƙananan matakan CEACAM6 wanda ya karbi pelareorep a hade tare da chemotherapy (haɗi zuwa PR, mahada zuwa poster). Baya ga kimanta aminci da inganci na pelareorep-atezolizumab magani, GOBLET kuma yana neman nuna yuwuwar CEACAM6 da T cell clonality a matsayin masu tsinkaya masu tsinkaya, wanda zai iya haɓaka yuwuwar samun nasarar karatun rajista na gaba ta hanyar ba da damar zaɓi na mafi dacewa marasa lafiya. .  

Seagen Inc. kwanan nan ya sanar da bayanai daga wani gwaji na asibiti na lokaci na 1 wanda ya hada SEA-CD40 tare da chemotherapy da anti-PD-1 a cikin marasa lafiya tare da PDAC na metastatic a taron shekara-shekara na ASCO GI da ke faruwa a San Francisco, Janairu 20 - 22, 2022. SEA -CD40 labari ne, bincike, nonfucosylated monoclonal receptor-agonist antibody kai tsaye zuwa CD40, wanda aka bayyana akan sel masu gabatar da antigen. A cikin ƙirar ƙira, haɗin SEA-CD40 da chemotherapy ya haifar da aikin antitumor wanda aka ƙara inganta tare da maganin anti-PD-1.

A cikin gwajin lokaci na 1 mai gudana, an haɗa SEA-CD40 tare da chemotherapy [gemcitabine da nab-paclitaxel (GnP)], da kuma anti-PD-1 (pembrolizumab), a cikin marasa lafiya na 61 tare da PDAC da ba a kula da su ba. Daga cikin waɗannan, marasa lafiya 40 sun karbi 10 mcg / kg kuma marasa lafiya 21 sun karbi 30 mcg / kg na SEA-CD40. Maɓalli na ƙarshe sun haɗa da ƙimar amsawar haƙiƙa (cORR) a kowane RECIST v1.1 ta mai bincike, tsira ba tare da ci gaba ba (PFS) da rayuwa gabaɗaya (OS) “Ayyukan farko yana ƙarfafawa bisa ga sakamakon ilimin chemotherapy na tarihi. Ana buƙatar ƙarin bibiyar rayuwa don sanar da matakanmu na gaba game da ciwon daji na pancreatic, "in ji Roger Dansey, MD, Babban Jami'in Lafiya a Seagen. "Muna ci gaba da ci gaba da ci gaba da gwajin lokaci na 2 na SEA-CD40 a cikin melanoma da kuma ciwon huhu na huhu."

Exact Sciences Corp. kwanan nan ya sanar da bayanan aiki don gwajin gwajin Cologuard na ƙarni na biyu (Multi- target stool DNA) wanda ke nuna jimlar 95.2% don ciwon daji mai launi (CRC) a ƙayyadaddun 92.4% don samfurori mara kyau da aka tabbatar ta hanyar colonoscopy. Binciken ƙananan ƙungiyoyi ya nuna 83.3% hankali don dysplasia mai girma, mafi hatsarin cututtuka na precancerous, da 57.2% ga duk raunuka masu tasowa. Za a gabatar da waɗannan bayanan Janairu 22 a ASCO GI a cikin wani fosta mai taken, "Tsarin Tsararraki Mai Manufa Na Biyu na Farko na DNA Ta Amince Ya Gano Ciwon Ciwon Canji da Ciwon Cutar Ciwon Ciki."

Cologuard shine farkon kuma kawai FDA-an yarda, gwajin DNA mara cin zarafi da ake amfani dashi don tantance matsakaita masu haɗari ga CRC. Madaidaicin Kimiyya yana haɓaka Cologuard na ƙarni na biyu don haɓaka ƙayyadaddun ƙayyadaddun ƙayyadaddun ƙwayar cutar kansa na gwajin, rage ƙimar ƙimar ƙarya da haɓaka ƙimar gano cututtukan da suka rigaya. Binciken ya nuna yuwuwar babban kwamiti mai nuna wariya na alamomin DNA na methylated da haemoglobin na fecal don cim ma duka a cikin yanayin duniyar gaske. Idan an amince da shi, gwajin Cologuard na ƙarni na biyu zai iya taimakawa wajen haɓaka ƙimar tantancewa yayin da ake tura mutane kaɗan zuwa bin diddigin ƙwayoyin cuta ba dole ba da kuma gano ƙarin ci gaba na precancers kafin su ci gaba zuwa cutar kansa, yana taimakawa hana cutar.

Bristol Myers Squibb kwanan nan ya sanar da Kwamitin Kula da Magunguna don Amfani da Dan Adam (CHMP) na Hukumar Magunguna ta Turai (EMA) ya ba da shawarar amincewa da Breyanzi (lisocabtagene maraleucel; liso-cel), CD19-directed chimeric antigen receptor (CAR) T cell far don kula da tsofaffi marasa lafiya tare da relapsed ko refractory (R / R) yada manyan B-cell lymphoma (DBCL), primary mediastinal babban B-cell lymphoma (PMBCL), da follicular lymphoma grade 3B (FL3B) bayan biyu ko fiye Lines. na tsarin jiyya. Hukumar Tarayyar Turai (EC) za ta sake duba shawarar CHMP, wacce ke da ikon amincewa da magunguna ga Tarayyar Turai (EU).

Kura Oncology, Inc., wani kamfani ne na likitanci wanda ya himmatu wajen tabbatar da alƙawarin madaidaicin magunguna don maganin cutar kansa, kwanan nan ya sanar da cewa Hukumar Abinci da Magunguna ta Amurka (FDA) ta ɗage aikin asibiti a matakin KOMET-001. 1b nazarin KO-539 a cikin marasa lafiya tare da relapsed ko refractory m myeloid cutar sankarar bargo (AML). An ɗaga ɗan ɗalibi na asibiti biyo bayan yarjejeniya tare da FDA akan dabarun ragewa Kamfanin don bambance-bambancen ciwo, sanannen bala'i mai alaƙa da bambance-bambancen wakilai a cikin jiyya na AML.